The financing secures funds to advance the clinical development of EpiEndo’s lead compound EP395, which entered phase I clinical trials in April, through Phase IIa, targeting COPD as a primary indication
The approval allows it to market its products in the country
The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.
_256_384.png)
MTL, with over 40 years of experience in packaging, caters to the requirements of the FMCG, F&B, homecare, personal care, agrochemicals, pharmaceutical, and liquor industries
This therapy may provide the first potential oral treatment for COVID-19, recognizing the global emergency of new SARS-CoV-2 variants
Idiopathic hypersomnia is a life-long condition, and the approval of Xywav will be instrumental in providing treatment for symptoms such as excessive sleepiness and difficulty waking, and in effectively managing this debilitating disorder
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
Sputnik V is a two-dose shot and has an efficacy of 91.6% against COVID 19
Anti-malaria API facility will be operational in 15-18 months
If approved it will bring a second source of MMR vaccine to the US market
Subscribe To Our Newsletter & Stay Updated
